# The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Study · id `cardio:ct-nct05505994` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05505994](<https://clinicaltrials.gov/study/NCT05505994>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05505994

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 340 participants.

## Technical summary

Registry record NCT05505994. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-28 (actual); primary completion 2024-02-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 340 participants (enrolled count; ClinicalTrials.gov record NCT05505994, source copy `cardio:ctgov-nct05505994-2024-04-04`, retrieved 2026-10-26)
- Started: 2022-09-28 (actual) (ClinicalTrials.gov record NCT05505994, source copy `cardio:ctgov-nct05505994-2024-04-04`, retrieved 2026-10-26)
- Primary completion: 2024-02-26 (actual) (ClinicalTrials.gov record NCT05505994, source copy `cardio:ctgov-nct05505994-2024-04-04`, retrieved 2026-10-26)
- Completion: 2024-09 (anticipated) (ClinicalTrials.gov record NCT05505994, source copy `cardio:ctgov-nct05505994-2024-04-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05505994, source copy `cardio:ctgov-nct05505994-2024-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05505994-2024-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
- Condition: Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Condition: Glucose Metabolism Disorders
- Condition: Metabolic Disease
- Condition: Endocrine System Diseases
- Intervention (Drug): DWP16001
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): DWP16001 Placebo
- Intervention (Drug): Dapagliflozin Placebo
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: de2830b7e1cf4dd3454c108c6b170fab25e18a54c5fd254dda6326d3cd5fdef0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
